People imagine an online prescription is either a magic button or a shady loophole. In real life, it is usually a boring workflow with a few predictable handoffs.
A licensed clinician reviews your information, decides whether a medication is appropriate, and then sends a prescription to a pharmacy that can legally dispense it. The details vary by provider, by state, and by whether a program uses brand name medications, compounded medications, or a mix of both.
You’ll learn what usually happens from intake to delivery, what slows things down, and what to verify before you pay. You will not get dosing advice, suitability advice, or medical outcome claims here. The goal is to make the process understandable.
Quick definitions
If you have ever felt lost in a portal, these are the words that tend to show up the most.
- A GLP-1 medication is a prescription drug in a class that acts on GLP-1 pathways. Some are used for diabetes care, and some are used for weight management depending on the product and the patient.
- eRx, or electronic prescribing, is when a clinician sends your prescription electronically to a pharmacy through an e-prescribing system rather than using paper, fax, or a phone call.
- Prior authorization, often shortened to PA, is an insurance coverage step. The insurer asks for documentation before it agrees to pay for a medication.
- Compounding is when a pharmacy prepares a medication for a specific patient need. Compounded drugs are not FDA-approved, and the practical details depend on the pharmacy, the program, and where you live.
- Asynchronous care means you submit information and a clinician reviews it later. You might get messages back and forth instead of a scheduled live visit.
The boundary lines
To keep this clean, here is what you will not see.
- No dosing guidance or titration advice
- No “is this right for you” decisions
- No medical outcomes, promises, or guarantees
- No sourcing advice outside a licensed clinical workflow
What you will get is the operational flow, the common delay points, and a practical set of questions you can use to reduce surprises.
The actors in the system
Most people talk about “the provider” like it is one person. In reality, it is a chain of roles that hand work to each other.
The GLP-1 telehealth platform is the website or app where you fill out forms, pay, and message support. The prescribing clinician is the physician, nurse practitioner, or physician assistant who reviews your information and makes the prescribing decision. The pharmacy is the entity that dispenses the medication, either through a retail network for brand name prescriptions or through a compounding partner when compounded medication is involved. The support team is usually non-clinical and handles logistics, billing, shipping questions, and basic troubleshooting.
If you want to diagnose delays, start with one question: which role is holding the baton right now?
Step 1: Intake happens first
Before anyone can prescribe, the program needs a clinical intake. That intake is where most “fast approval” claims live, because it is the first gate.
At a minimum, intake usually collects the basics like age, height, weight, medical history, current medications, and allergies. Many programs also include screening questions designed to flag situations that require a closer look.
Some programs add verification steps. You may see requests like:
- Photo ID upload
- A selfie or short video
- A blood pressure reading
- Recent lab work, or a lab order
That extra friction can feel annoying, but it is also a sign that the program is verifying more than it is assuming.
Step 2: Eligibility screening happens in layers
Many platforms run an early screening step before a clinician ever reviews your case. It is not the prescription. It is triage.
This is where a platform typically checks whether you meet basic program criteria, whether anything triggers a manual review lane, and whether your medication list suggests possible interaction concerns.
If you fail this first screen, you may get a quick “not eligible” message and a refund path. If you pass, your case moves forward to clinical review.
Step 3: A clinician reviews your case
A prescription begins with a clinician review. This is the part that separates a real prescribing workflow from a marketing funnel.
The review usually starts with completeness. Missing medication lists, unclear history, and unanswered questions slow everything down because they create a loop. After that, the clinician evaluates whether anything in your history suggests the medication may not be appropriate and whether labs, vitals, or clarifying details are needed.
How that review happens depends on the program.
Some programs use asynchronous review for most people. You submit intake, a clinician reviews it later, and you receive a message with next steps. This can be efficient, but it can feel opaque if the rules are not explained and you cannot tell who reviewed what.
Other programs require a video or phone visit, especially for first-time prescriptions or certain states. That can add scheduling friction, but it often improves clarity because you can ask questions in real time.
A hybrid model sits in the middle. You submit intake first, a clinician reviews, and a visit is only scheduled if something needs discussion or verification.
Step 4: Routing happens before dispensing
A clinician can approve your case, but the dispensing route determines what happens next.
One common route is brand name medication through a retail pharmacy. In that path, insurance becomes a major variable. Coverage checks, prior authorization, and inventory often decide the timeline.
Another route is compounded medication through a partner compounding pharmacy. In that path, there is often no insurance step, so the process can feel faster and more centralized. However, it is also a higher-sensitivity area because compounded drugs are not FDA-approved. A transparent program makes it easy to verify the dispensing pharmacy, the licensing, and the standards being used.
A simple routing decision tree
Routing is not random. It usually follows coverage, availability, and program design.
Here is the plain-language logic most people experience:
- If insurance coverage is available and the program supports insurance workflows, you often see the brand name route.
- If coverage is not available, the patient is cash pay, or the program is built around a partner pharmacy lane, you may see a compounded route if the program offers it.
Routes can change later. It usually happens because something upstream changes, such as coverage decisions, stock, or program policy.
Step 5: The prescription is sent electronically
Once the clinician finalizes the decision, the prescription is usually sent electronically through an eRx system. That matters because it creates a documented order tied to a licensed prescriber, and it creates timestamps that often drive refill and billing rules.
A key detail gets missed here: “sent” does not mean “filled.” It means the pharmacy has received the order and can begin its own verification and processing.
Step 6: The pharmacy verifies and processes
Pharmacies do not just print a label and ship. They verify the prescription and confirm they can legally dispense.
In practical terms, that can include confirming the prescriber credentials, checking identity details, confirming shipping rules for your address, and verifying inventory or fulfillment capacity.
Once verification is complete, fulfillment begins. In mail-order style workflows, this is where picking, packing, packaging rules, labeling, inserts, and tracking numbers come into play.
Step 7: Instructions and next steps show up
Instructions often come from both the pharmacy and the telehealth platform. You might get pharmacy inserts and labeling, plus a portal summary that explains what happens next, when to check in, and how refills are handled.
Strong programs make the next step obvious and write the rules down. Weak ones give you a tracking number and then disappear.
Common timelines with realistic ranges
Timelines vary, but people still need ranges to plan. Think of these as “often seen” ranges, not promises.
- First clinical review after intake: commonly 24 to 72 hours in faster systems, longer when queues are backed up
- Clarification loop (when questions are asked): often adds a few days because your case pauses and re-enters a queue
- Pharmacy processing after the prescription lands: commonly 1 to 5 business days depending on backlog and batching
- Shipping after label creation: often 1 to 3 business days plus weekends and carrier variability
- Prior authorization: often a few days to a couple of weeks, longer if more documentation or appeals are needed
- Refill buffers: many programs use 7 to 14 days before run-out when a review step exists
Two-lane timeline
It helps to see two common lanes side by side.
In a brand name plus insurance lane, the friction is usually insurance. Intake and clinical review might be quick, but then the process goes through a retail pharmacy claim, a possible prior authorization, and pharmacy inventory. Delays often show up in paperwork and stock availability.
In a cash pay partner pharmacy lane, the friction is usually processing and shipping. The clinician approves, the prescription lands at a partner pharmacy, and then fulfillment and carrier timing drive delivery. Delays often show up in pharmacy backlog, batching schedules, and shipping issues.
Where delays really come from
Most delays come from handoffs, not from one person “ignoring” you.
The common causes are boring and repetitive:
- Incomplete intake that forces clarification
- A clarification loop that restarts queue time
- State constraints that add steps like live visits or documentation
- Insurance friction, especially prior authorization and appeals
- Pharmacy capacity limits that create batching and backlogs
- Inventory issues that block a dose from being filled
A useful mental model is a relay race. The baton gets dropped at handoffs.
What you can confirm versus what becomes guesswork
You can usually confirm whether a licensed prescriber is making the decision, whether a live visit is required, whether labs are required, whether the route is retail pharmacy or a partner pharmacy, and what the pricing model includes.
What often becomes guesswork is the time to first review, time for dose-change reviews, refill cutoff rules, what happens after a denial, and what happens during stockouts.
When a program is vague here, it is not always malicious. Sometimes it is avoidance of commitments. Either way, uncertainty becomes part of the cost.
What to verify about the program and the pharmacy
You can stay operational and still protect yourself.
Here is what should be easy to confirm before you pay:
- A licensed prescriber is responsible for the prescribing decision
- The dispensing route is clear (retail pharmacy, partner pharmacy, or both)
- Refill rules are written down, including cutoff windows and review timing
- Refund and denial policies are explicit
- The dispensing pharmacy is identifiable and appropriately licensed for your state
If compounded medication is offered, a transparent program makes it easy to confirm pharmacy identity, where it is located, and what standards it follows.
Questions to ask support
A few well-aimed questions reduce most surprises.
- Start with clinician review. Ask what the common time to first review is after intake, and ask whether follow-up questions restart the queue. If labs or vitals are needed, ask what pauses and what continues.
- Then ask about routing. Ask whether prescriptions go to a retail pharmacy, a partner pharmacy, or both. Ask what causes the route to change later, such as coverage, stock, policy, or dose changes.
- Ask about pharmacy and shipping. Ask what the typical processing time is after the prescription lands. Ask whether shipments are batched on specific days. Ask how delays, lost packages, or returns are handled.
- If insurance is involved, ask who submits prior authorization, what documents are typically included, and what range of time you should expect for a decision. Ask how you will get status updates and who you should contact for follow up.
- Finally, ask about refills. Ask when you should request a refill relative to your run-out date. Ask whether refill approval is automatic or reviewed each month. Ask what the typical time is from refill request to shipment or pharmacy pickup.
A note on compounding without hype
Compounded drugs are not FDA-approved. That means FDA does not review them for safety, effectiveness, or quality the same way it reviews approved drugs. Compounding can be legitimate in certain situations, but rules and availability vary, and the pharmacy matters.
A reasonable expectation is that a transparent program will make pharmacy identity, licensure, and standards easy to verify. If the answer is vague, that is a transparency problem.
What to take away
An online GLP-1 prescription is a documented clinical decision plus a pharmacy fulfillment process.
If you understand the handoffs, you can understand the delays.
If the route is clear and the rules are written down, you can predict what happens next.
If you cannot predict what happens next, the uncertainty becomes part of what you are paying for.
Sources and references
- FDA: Compounding and the FDA, Questions and Answers
- FDA: Human Drug Compounding Laws (503A and 503B context)
- FDA: FDA’s concerns with unapproved GLP-1 drugs used for weight loss
- NAIC: What Is Prior Authorization?
- CMS: Prior Authorization and Pre-Claim Review Initiatives
- Surescripts: e-Prescribing overview